I guess we'll agree to disagree. The real science says differently. I think both products will take market share, but the more difficult wounds will use Grafix. Also, Cartiform and BIO4 are game changers. Good luck with your MiMedx investment. I continue to trade it.
Sentiment: Strong Buy
I can tell you the live cells offer no advantage in avascular wounds. There are added costs with storage, limited shelf life, difficulty in usage and handling. You are wrong on many accounts. Grafix may play a minor role in wound care. Odiris other products seem interesting.
From a strategic standpoint MiMedx has become the clear leader in advanced wound care therapy. We generally know approximately the number of patients being serviced by our competitors and we certainly far exceeded our largest competitor by the end of last year and we’re way ahead of the others. I predict by the end of 2015, our major competitor Organogenesis, would have deteriorated to the point that they will have a very limited presence in advanced wound care. The saying that their executives decisions over the last decade left them as such a burnout position, with added to that outdated technology and no new innovations.
Jmho but, I believe that a buyout is when certain conditions
1. 90% US coverage of products.
2. 50% Global coverage of products.
Coverage for me is loosely defined as Government approval
and/or insurance approved use.
This may take until 2020 and management seems capable of
making it happen..
Why? The healing properties of these products are amazing !!
OWT has disappeared the same way our national heritage has........ 2015 buyout is ridiculous..... MDXG monopoly on wound care is ridiculous..........this board is an echo chamber with nothing new
Seems highly unlikely that 2015 buyout would occur as the FDA stated it won't render a ruling on minimal manipulation until end of year/early 2016. It seems that issue will be hanging around for the rest of this year. If this wasn't an issue then this company should've already be purchased.
According to management (Pete), Organogenesis late in 2015 will become non existent in wound care.
it seems with the latest smear campaign and Organogenesis grasping for air, Pete may have nailed it.
looks like MiMedx will have a monopoly on wound care.
I wasn't aware that a final buyout price, or buyout date had been determined. I recall old_wisetrader saying the buyout would still occur in 2015. I'm certain Pete will command a premium for AmnioFix and CollaFix, but I'm uncertain how large that premium will end up. As it relates to the stock market, I've learned to expect the unexpected.
That is very ambitious Earth! That price at the end of the year would suggest a huge buyout price in 2016......much higher than the expected $20pps-----is that the way you see it?
The company was well ahead of schedule on their hiring of new salesmen. Also, Dr. Don Fetterolf has done an excellent job building insurance reimbursement on the commercial side this year. I agree with you Doc. This bodes well for good revenue growth in 2016 and 2017. It will be even better if the company starts seeing some international revenue.
I don't know if the was addressed to me or not Doc, but I think $16 - $18 by the end of the year. If I had thought any differently, then I could have used the index fund buying as an opportunity to sell some stock for $11.50 or better.
Yep Tipsy----huge drop this week. Hopefully a big earnings announcement can push it over $12 but the resistance to $12 is monstrous.
"str8 I like your enthusiasm however forget about a breakout
I've been a long term long but now ready for the index reshuffle create the predictable "bomb" in July.
Don't believe me, look at last year"
I have to admit that you nailed it with this prediction Tipsy. I'm still of the opinion though that the stock was at $11.97 in December, and the news in 2015 has been very positive. The drop earlier this year was caused by that phony qui tam action and increased shorting. The drop since July 1 is directly attributable to increased shorting activity too.
As long as we are talking about history and last year, don't be surprised if this stock makes an entire year of gains in 60 days, and my bet is those gains come late in 2015. More shares now are in the hands of institutions yet the short interest keeps increasing anyhow. This scenario is leading to a major showdown. It is hard not to expect volatility in this stock.
Can't even get the last 2 letters of a 4 letter symbol right.....pretty obvious. I see this as a great sign when these new Orgo posters arrive. We're headed to a higher level soon. GLTA
Sentiment: Strong Buy
the next news should be 1) release date for the 2q EPS, and 2) preliminary 2q revenue results........... guidance is $44-46 million.... I expect some of this to come today or tomorrow, but not sure how the holiday tomorrow will impact this.......